Syringe Driver Survey Database migration to MedicinesComplete - January 2023

Syringe Driver Survey Database has moved to MedicinesComplete and is no longer available on palliativedrugs.com.

It has been renamed to PCF’s Syringe Driver Database and is now accessed through Drug Compatibility Checker.

Drug Compatibility Checker, through MedicinesComplete is a new tool providing essential compatibility knowledge to support the administration of injectable drugs combining published data and clinical practice reports.

Find out more about Drug Compatibility Checker:https://about.medicinescomplete.com/publication/drug-compatibility-checker/

If you have a subscription to Palliative Care Formulary through MedicinesComplete, you will have access to PCF’s Syringe Driver Database through Drug Compatibility Checker, at no charge through 2023. 

To contribute to PCF’s Syringe Driver Database please continue to submit a clinical practice report using palliativedrugs.com here: https://www.palliativedrugs.com/syringe-driver-database.html

To learn more about a subscription to the Palliative Care Formulary through MedicinesComplete, please contact us here: https://info.medicinescomplete.com/sales

If you have any questions regarding access to PCF’s Syringe Driver Database or would like to renew your subscription to Palliative Care Formulary, please contact pharmpress-support@rpharms.com.

---

High-dose loperamide: reports of serious cardiovascular events

28th September 2017

The MHRA has warned that serious and fatal cardiovascular events including QT prolongation, torsades de pointes, and cardiac arrest have occurred in patients who have taken high doses of loperamide as a drug of abuse or misuse. Similar warnings have been issued by the US FDA. The daily doses reported range from 40−800mg (the recommended maximum dose is 16mg/24h). Health professionals are reminded that naloxone can be used if symptoms of overdose occur, although due to the long duration of action, repeat treatment may be required.

Editors note. Doses higher than recommended are sometimes used in palliative care, however this practice should be avoided in patients at risk of cardiac arrhythmia or in a patient taking a CYP3A4 inhibitor; rarely cardiac arrhythmias have been reported in these patients even when taking therapeutic doses (see our loperamide monograph).

click here to view